BionimeTPE:4737 -0.18%65 OCF Margin % is 15.56% as of Dec. 2025, which is 26% above its 10-year median of 12.32. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bionime ranks better than 89.33% on this metric.
The historical rank and industry rank for Bionime's OCF Margin % or its related term are showing as below:
TPE:4737'
s OCF Margin % Range Over the Past 10 Years
Min: 1.01 Med: 12.32 Max: 26.91
Current: 26.91
During the past 13 years, the highest OCF Margin % of Bionime was 26.91%. The lowest was 1.01%. And the median was 12.32%.
TPE:4737's OCF Margin % is ranked better than 89.33% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs TPE:4737: 26.91
Bionime OCF Margin % Related Terms
Bionime OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bionime's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bionime's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bionime's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a OCF Margin % of 15.56% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bionime and its competitors. This is 26% above median its historical median of 12.32. Over the past decade, Bionime's OCF Margin % has ranged from 1.01 to 26.91. According to the industry distribution chart, Bionime ranks #87 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 10.7%.
Is Bionime's OCF Margin % too high?
Bionime's current OCF Margin % of 15.56% is 26% above median its 10-year median of 12.32. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 26.91. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Bionime's value of 15.56% is 165.5% above this industry median. Based on the distribution chart, Bionime ranks #87 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #87 out of 815 companies for OCF Margin %. This places Bionime in the top 11% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Bionime's value of 15.56% is 165.5% above this benchmark. Historically, Bionime's own OCF Margin % has ranged from 1.01 to 26.91 over the past decade. While the company's 10-year median is 12.32 vs. the industry median of 5.86, Bionime has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionime's current OCF Margin % of 15.56% is 165.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current OCF Margin % is 15.56%, which is 26% above median its own 10-year median of 12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$57.00 — trading 3.3% below its estimated fair value. The current OCF Margin % is 15.56%, which is 26% above median its 10-year median of 12.32 and 165.5% above the Medical Devices & Instruments industry median of 5.86. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bionime (TPE:4737), the current OCF Margin % is 15.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$57.00 is trading 3.3% below its estimated GF Value™ of NT$58.96.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
OCF Margin %: 15.56% (26% above median its 10-year median of 12.32)
GF Value™: NT$58.96 vs. price of NT$57.00 (3.3% below fair value)
Industry Position: 165.5% above the Medical Devices & Instruments median (#87 of 815)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
